Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker

Garimella, Veerabhadram; Hussain, Tasadooq; Agarwal, Vijay; Radhakrishna, Selvi; Fox, John N.; Kneeshaw, Peter J.; Long, Ervine D.; Mahapatra, Tapan K.; McManus, Penelope L.; Lind, Michael J.; Drew, Philip J.; Cawkwell, Lynn

Abstract

Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past. Aromatase inhibitors may be more beneficial than tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to retrospectively evaluate a series of elderly women with ER-positive breast cancer treated with primary letrozole therapy as sole therapy with a minimum of 5 years follow up. To identify possible predictive biomarkers a pilot immunohistochemical analysis was performed to assess the expression of PR, HER2, EGFR, BCL2 and p53. A total of 45 women, aged more than 70 years with a diagnosis of ER-positive breast cancer that was treated with primary letrozole therapy were identified. A case note review was undertaken to obtain clinical information. Formalin fixed paraffin embedded tumour tissue from diagnostic core biopsies was available for all patients. Immunohistochemical analysis was performed to establish the protein expression status of p53, PR, HER2, EGFR and BCL2. The mean age of the 45 patients was 87 years (range 70–101). Clinical benefit was seen in 60% of the patients. Median progression free survival was 53 months (95% CI – 34–72) and the median time to progression was 43 months (95% CI – 22–64). BCL2 was expressed in 45/45 (100%); PR in 38/45 (84%); EGFR in 13/45 (28%); HER2 in 9/45 (20%) and p53 in 5/45 (11%) of tissue samples. Positive expression of p53 was associated with poor progression free survival (p = 0.03) in this pilot study. This study demonstrates that letrozole as sole treatment appears to be a suitable treatment option for elderly patients with ER-positive breast cancer who are not fit for, or decline, surgery. The analysis of p53 in a larger study is warranted in order to assess its role as a biomarker in this patient group.

Citation

Garimella, V., Hussain, T., Agarwal, V., Radhakrishna, S., Fox, J. N., Kneeshaw, P. J., Long, E. D., Mahapatra, T. K., McManus, P. L., Lind, M. J., Drew, P. J., & Cawkwell, L. (2014). Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker. International journal of surgery, 12(8), 821-826. https://doi.org/10.1016/j.ijsu.2014.06.009

• Journal Article Type: Article
• Acceptance Date: Jun 20, 2014
• Online Publication Date: Jul 7, 2014
• Publication Date: 2014-08
• Deposit Date: Aug 25, 2015
• Publicly Available Date: Nov 23, 2017
• Journal: International journal of surgery
• Print ISSN: 1743-9191
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 12
• Issue: 8
• Pages: 821-826
• DOI: https://doi.org/10.1016/j.ijsu.2014.06.009
• Keywords: Aromatase inhibitor; Breast cancer; Elderly; ER; p53
• Public URL: https://hull-repository.worktribe.com/output/377908
• Publisher URL: http://www.sciencedirect.com/science/article/pii/S1743919114001915
• Additional Information: Author's accepted manuscript of article published in: International journal of surgery, 2014, v.12, issue 8
• Contract Date: Nov 23, 2017